Key result
Coronary microvascular dysfunction was not associated with worse residual angina at 1 year overall, but in patients with focal CAD, concomitant CMD was associated with less symptomatic improvement after PCI.
Why the study?
Coronary microvascular dysfunction has been proposed as a mechanism underlying residual angina after PCI, but its impact on patient symptoms required investigation.
Does coronary microvascular dysfunction worsen patient-reported symptoms in patients with hemodynamically significant CAD undergoing PCI?
Cohort (n=201)
Yes
Does coronary microvascular dysfunction worsen patient-reported symptoms in patients with hemodynamically significant CAD undergoing PCI?
CMD is common in patients with flow-limiting CAD and limits symptomatic benefit from PCI specifically in those with focal epicardial disease.
Answers are grounded in this paper and cite their sources.
CMD was not linked to residual angina overall but associated with less PCI benefit in focal CAD; leaves open whether microvascular testing should inform revascularization.
BACKGROUND: Coronary microvascular dysfunction (CMD) has been proposed as a mechanism underlying residual angina after percutaneous coronary intervention (PCI). OBJECTIVES: The objective of the study was to investigate the impact of CMD on symptoms in patients undergoing PCI. METHODS: Patients with hemodynamically significant coronary artery disease (CAD) (fractional flow reserve ≤0.80) were included. CAD was classified as focal or diffuse using the pull back pressure gradient (PPG) (diffuse CAD defined as PPG <0.62). CMD was defined as microvascular resistance reserve <3.0. The Seattle Angina Questionnaire (SAQ) was administered at baseline and 1 year. RESULTS: Among 201 patients (mean age 68.5 ± 10.1 years; 71% male), CMD was present in 75 (37.3%), with no difference between focal and diffuse CAD (41% vs 34%; P = 0.35). At baseline, CMD was associated with more severe symptoms without reaching statistical significance (SAQ summary score 64.0 ± 25.3 vs 69.6 ± 21.0; P = 0.09). At 1 year, symptoms were similar between groups (SAQ summary score 87.6 ± 16.0 vs 89.4 ± 16.4; P = 0.47). A significant interaction between PPG and microvascular resistance reserve was observed for residual angina (P for interaction = 0.015); patients with focal CAD and concomitant CMD had the highest burden of residual symptoms. CONCLUSIONS: CMD is present in approximately one-third of patients undergoing PCI and occurs with similar frequency in focal and diffuse CAD. CMD alone was not associated with residual angina. However, its clinical relevance varied according to the epicardial disease pattern: in focal CAD, concomitant CMD was associated with less symptomatic improvement after PCI, whereas in diffuse CAD, residual symptoms appeared to be driven predominantly by persistent epicardial disease.
No takes yet. Share an insight, caveat, or question.
Bouisset et al. (2026) conducted a cohort in Hemodynamically significant coronary artery disease undergoing PCI (n=201). Coronary microvascular dysfunction (CMD) vs. Normal microvascular function was evaluated on Seattle Angina Questionnaire (SAQ) summary score at 1 year (p=0.47). Coronary microvascular dysfunction was not associated with worse residual angina at 1 year overall, but in patients with focal CAD, concomitant CMD was associated with less symptomatic improvement after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: